Japan

Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated. BMI's Pharmaceutical Expenditure Model reveals... 2013-04-24

A prescription medicine that treats a 'lifestyle' disease has been launched for the first time as an over-the-counter (OTC) drug in Japan. This is significant given that previous such... 2013-04-18

BMI View: We believe drugmakers based in emerging markets will expand their presence in developed countries. Although firms in developing countries enjoy low operating costs, they have... 2013-03-14

BMI View: Japan's renewed interest in stem cell research will help the country maintain its position alongside South Korea as a pre-eminent innovator in biomedical sciences in Asia.... 2013-03-05

BMI View: Shockwaves from the biennial drug price cut continue to impact pharmaceutical firms in Japan. We highlight that domestic pharmaceutical companies are affected more than overseas... 2013-02-28

BMI Core View: Uptake of generic drugs in the wake of patent expirations will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies,... 2013-01-11

BMI View: Considering Japan's lacklustre economic trajectory and recently unsettled political environment, as well as its extremely challenging demographic profile, the country's healthcare... 2012-07-09